Case Control Study

Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients

Magdy Fouad, Mohamed El Kassas, Elham Ahmed, Reem El Sheemy

ORCID number: Magdy Fouad 0000-0001-8065-5581; Mohamed El Kassas 0000-0002-3396-6894; Elham Ahmed 0000-0002-7182-3245; Reem El Sheemy 0000-0001-8158-8878.

Author contributions: Fouad M and El Kassas M conceptualized the idea and design; El Sheemy R drafted, revised and edited the manuscript; all authors participated in and supervised patients’ treatment and follow-up, revised and approved the final version of the manuscript.

Institutional review board statement: The study protocol was approved by the Institutional Research Board at the Faculty of Medicine, Minia University, Egypt. Informed written consent was obtained from all patients of the study. This research was performed in agreement with the guidelines of the 1975 Declaration of Helsinki.

Informed consent statement: Informed consent was obtained from all individual participants included in the study.

Conflict-of-interest statement: All authors declare that they do not have any conflict of interest.

Abstract

BACKGROUND
Insufficient and contradictory data are available about the relation between direct-acting antivirals (DAAs) and hepatocellular carcinoma (HCC) development in patients with hepatitis C virus (HCV).

AIM
To analyze differences in basic clinical, radiological, and laboratory characteristics in addition to tumor behavior upon HCC diagnosis between patients with and without a previous history of DAAs exposure.

METHODS
This multicenter case-control study included 497 patients with chronic HCV-related HCC, allocated into one of two groups according to their history of antiviral treatment for their HCV.

RESULTS
Group I included 151 HCC patients with a history of DAAs, while 346 patients who had never been treated with DAAs were assigned to group II. A significant difference was observed between both groups regarding basic assessment scores (Child, MELD, and BCLC), which tended to have more advanced liver disease and HCC stage upon diagnosis in group I. However, serum albumin was inadequate.
Hepatocellular carcinoma; Direct-acting antiviral treatment; Hepatitis C; Volume 13
November 27, 2021
1744

Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of HCC after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021; 13(11): 1743-1752

INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related mortality worldwide[1]. In Egypt, HCC is a significant public health problem responsible for 33.63% and 13.54% of all cancers in males and females, respectively[2]. On the other hand, hepatitis C virus infection (HCV) is considered a leading cause of chronic liver disease in Europe, the United States, and many other countries, including Egypt[3,4]. The risk of HCC development in HCV-related liver cirrhosis is 2% to 8% per year[5]. Multiple studies and meta-analyses demonstrated during the era of interferon (IFN)-based therapy that HCV eradication decreased the risk of hepatocarcinogenesis regardless of fibrosis stage[6,7]. Furthermore, these studies showed that the achievement of sustained virologic response (SVR) after IFN based treatment is directly related to reduced incidence of HCC and increased survival rates[8].

In 2014, the introduction of the more effective direct-acting antivirals (DAAs) for HCV treatment was generally expected to benefit all patients, including those who were not permitted to be treated with IFN-based therapy[7]. However, unexpectedly, the clinical use of DAAs has evoked a significant dilemma about the relationship between DAAs and the development of HCC. Some studies have suggested a direct relation between DAAs and the development of HCC, while others have insisted that DAAs are protective against HCC development[7].

In 2016, the first report in this context showed an unexpectedly high recurrence rate of previously treated HCC after DAAs exposure[6]. This initial report was followed by another retrospective study conducted in Italy which included 344 patients with HCV-related cirrhosis who received different DAA regimens; 91% achieved SVR. The patients were followed for 24 wk. The study revealed a 29% recurrence rate for those with a history of HCC and a 3.16% incidence rate (de novo HCCs) in those without a history of prior HCC irrespective of the used DAA regimen[6].

Core Tip: Despite the introduction of newer direct-acting antivirals (DAAs), hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) will continue to be a significant public health concern in the coming decades. Post-treatment HCV-related HCC has been discovered to be an emerging issue due to unmet needs for early HCC identification and intervention. In addition, we found that aggressive tumors were more common in DAAs exposed patients, which needs to be investigated further in prospective studies with larger cohorts and necessitates proactive screening for HCC in HCV-treated patients via public or private pharmacovigilance programs.

Data sharing statement: No additional data are available.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Country/Territory of origin: Egypt

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works upon this work non-commercially, distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works.

Received: April 15, 2021
Peer-review started: April 15, 2021
First decision: June 15, 2021
Revised: June 30, 2021
Accepted: September 29, 2021
Article in press: September 29, 2021
Published online: November 27, 2021
P-Reviewer: Gaspar R, Sachu A, Shi YJ
S-Editor: Wang LL
L-Editor: A
P-Editor: Wang LL

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Key Words: Hepatocellular carcinoma; Direct-acting antiviral treatment; Hepatitis C; Tumor behavior; Occurrence

Citation: Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021; 13(11): 1743-1752

DOI: https://dx.doi.org/10.4254/wjh.v13.i11.1743

URL: https://www.wjgnet.com/1948-5182/full/v13/i11/1743.htm
In addition to HCC recurrence, the different biological behavior of HCC in DAAs exposed patients, and the pattern of recurrence after DAA treatment has also been reported in studies coming from various countries. For example, in 2017, Reig and his colleagues reported more aggressive HCC recurrence after DAA treatment, as defined by an advanced Barcelona Clinic Liver Cancer (BCLC) stage[6]. Moreover, Renzulli et al[10] found a more aggressive HCC recurrence pattern with vascular invasion evidence after DAA therapy.

This study aimed to analyze differences in basic clinical, radiological, and laboratory characteristics and tumor behavior upon HCC diagnosis between patients with and without a previous history of DAAs exposure.

MATERIALS AND METHODS

Study design
The current study is a multicenter retrospective case-control study designed to compare the basic demographic, laboratory, and radiological criteria of HCC in patients with a history of DAAs treatment for their chronic HCV infection compared to HCC patients with no previous history of HCV antiviral treatment. Patients were recruited from December 2016 to April 2019 from Minia university hospital and Minia fever hospital, Minia, Egypt. Study patients were assigned to one of 2 groups according to previous DAAs exposure. The first group included 151 HCC patients who were previously treated with DAAs (Group I). According to a standardized treatment protocol, all patients were treated in one of the specialized viral hepatitis treatment centers affiliated to the Egyptian National Committee for Control of Viral Hepatitis. Group II included 346 HCC patients with the first presentation as HCC and no history of antiviral treatment for their HCV infection. Patients with combined HBV or HIV infections and patients with extrahepatic malignancies were excluded from the study.

Methods
All patients were recruited and diagnosed according to EASL guidelines and updated AASLD practice guidelines for managing HCC and BCLC guidelines[11-13]. In addition, baseline demographic, clinical, laboratory, and radiological criteria were studied. The Child-Turcotte Pugh score (CTP), Model for End-stage Liver Disease (MELD) score, BCLC score, and FIB 4 as a non-invasive marker for fibrosis were calculated and presented.

Lines of treatment for HCV have been verified as well as the viral response. In addition, all baseline characteristics, laboratory, radiological and medical scores were compared between the two groups.

The study was performed according to the ethical guidelines of the 1975 Declaration of Helsinki after approval from the Research Ethics Committee for human subject research at the Faculty of Medicine, Minia University (Serial: 165: 2/2019) on Feb 25, 2019. In addition, written informed consent was obtained from all participants before enrolment in the study.

Statistical analysis
Statistical analyses were performed using IBM SPSS advanced statistics, version 26 (SPSS Inc., Chicago, Illinois, USA). Numerical data were presented as mean ± SD and median (range), whereas categorical data were presented as number (percent). The Mann-Whitney U-test and the \( \chi^2 \)-test are used when appropriate. Statistical significance is considered if \( P \) value is less than or equal to 0.05.

RESULTS
This study included 497 patients with chronic HCV-related HCC, allocated into one of two groups according to their history of antiviral treatment for their HCV. Group I included 151 patients with chronic HCV and HCC who were previously treated with DAAs. Group II included 346 patients representing all participants recruited in the same period with HCV-related HCC and age and sex-matched with group I. Most of the studied patients in both groups were males: (76.2%) and (72.0%) (\( P \) value 0.33), with a mean age of 60.2 years and 59.8 years in groups I and II, respectively (\( P \) value 0.70) (Table 1). Regarding the received DAAs regimen in group I patients, 44.4% of patients...
Table 1 Basic demographic data and underlying liver status in both groups

|                  | Group I                          | Group II                         | P value |
|------------------|----------------------------------|----------------------------------|---------|
|                  | HCC with previous DAAs (n = 151) | HCC without previous DAAS (n = 346) |         |
| Age (mean ± SD)  | 60.17 ± 7.75                     | 59.84 ± 9.12                     | 0.70    |
| Gender           |                                  |                                  | 0.33    |
| Female           | 36 (23.8)                        | 97 (28.0)                        |         |
| Male             | 115 (76.2)                       | 249 (72.0)                       |         |
| Residence        |                                  |                                  | 0.28    |
| Rural            | 131 (86.8)                       | 287 (82.9)                       |         |
| Urban            | 20 (13.2)                        | 59 (17.1)                        |         |
| BCLC             |                                  |                                  | <0.001a|
| 0                | 5 (3.3)                          | 15 (4.3)                         |         |
| A                | 47 (31.1)                        | 134 (38.7)                       |         |
| B                | 17 (11.3)                        | 68 (19.7)                        |         |
| C                | 49 (32.5)                        | 50 (14.5)                        |         |
| D                | 33 (21.9)                        | 79 (22.8)                        |         |
| MELD (mean ± SD) | 14.35 ± 5.041                    | 36.10 ± 30.22                    | <0.001a|
| CTP score        |                                  |                                  | 0.04    |
| A                | 50 (33.1)                        | 88 (25.4)                        |         |
| B                | 65 (43.0)                        | 138 (39.9)                       |         |
| C                | 36 (23.8)                        | 120 (34.7)                       |         |
| FIB4             |                                  |                                  | <0.001c|
| mean ± SD        | 3.25 ± 9.87                      | 7.11 ± 7.68                      |         |
| Median           | 0.023                            | 4.49                             |         |
| IQR              | 4.51                             | 6.2                              |         |
| HCC detection time after stop of DAAS | Range: 1-72 mo Median: 8 mo | -                                |         |

*aP < 0.05.

*bP < 0.001.

HCC: Hepatocellular carcinoma; MELD: Model for end stage liver disease; CTP: Child Turcotte-pough; BCLC: Barcelona cancer liver clinic.

received sofosbuvir/daclatasvir (SOF/DAC), 40.1% received SOF/DAC/RBV, 13.2% received SOF/RBV, and only 2% received SOF/RBV/PEG IFN. Figure 1 shows patients’ distribution among various treatment regimens and treatment duration, in addition to treatment viral response.

Notably, significant differences were observed between the two groups regarding the case assessment scores that reflect the severity of the underlying liver condition upon HCC discovery. A total of 34.7% of patients in group II were CTP class C, and only 23.8% of group I patients were class C. Mean MELD score in group I was 14, while the mean MELD in group II was 36 (P value < 0.001). Moreover, a significant difference was observed in the BCLC score (P value < 0.001). A significant difference was encountered in FIB4 as a method for non-invasive fibrosis assessment with a mean FIB4 of 3.25 in group I, compared to 7.11 in group II (P value < 0.001). Basic demographic data and underlying liver status in both groups are detailed in Table 1. The time between stopping DAAs and the development of HCC ranged from 1 to 72 mo with a median of 8 mo.

When comparing both groups’ clinical data, no significant differences were observed except in the current smoking status, which was significantly increased in group I compared to the other group (P value 0.005). On the other hand, a significant history of blood transfusion was observed in patients with no previous history of DAAs (P value 0.01); cellular decompensation in the form of hepatic encephalopathy is...
significantly observed in patients with no previous history of DAAs (P value 0.01). Detailed clinical data of the two studied groups are well presented in Table 2.

Comparing laboratory data in both groups, hemoglobin level and total leukocytic count were significantly different (P values are 0.02 and 0.004, respectively). Median ALT in group I was 77 IU in comparison to 54 IU in group II (P value 0.001). Mean albumin in groups I and II was (3.3 and 2.9 respectively) (P value 0.004), and mean urea in groups I and II was (40 and 54 respectively) (P value 0.04). Median AFP in group I was 184 in comparison to 60 in group II (P value < 0.001). An illustrated comparison of all laboratory data is presented in Table 3.

Regarding the radiological characters of HCC in both groups, HCC in group I patients was more multifocal (53%) in comparison to (25%) in group II (P value < 0.001). Moreover, HCCs in group I patients tended to present with a bigger tumor size at the initial presentation than group II patients. More precisely, less than 1% of group I patients were presented with tumors less than 2 cm, while more than 15% of group II patients presented with tumors less than 2 cm (P value < 0.001), indicating more aggressive tumor behavior associated with the previous history of DAAs. The right lobe was the dominant victim in both groups. Early vascular invasion was significantly higher in group I compared to group II as evidenced radiologically by portal vein thrombosis (PVT), which present in 45% of group I patients and only 21% of group II patients (P value < 0.001), all radiological data for HCCs in the studied patients are detailed in Table 4.

**DISCUSSION**

Chronic HCV infection is a significant risk factor for developing liver cirrhosis in approximately 20%-30% of patients with subsequent increased risk for HCC development in those patients with an estimated annual incidence of 3.5%[14]. This risk is shown to be lower in patients with chronic HCV infection without cirrhosis and in patients who succeeded in achieving eradication, as proved by their SVR[15]. Despite the notable decrease in the overall incidence of HCV infection, its prevalence in HCC patients is still high[16]. Surprisingly, HCC development’s risk is continuous in HCV-induced liver cirrhosis even after viral eradication and SVR achievement[16]. During the interferon-based treatment era, successful viral eradication decreases the risk for HCC and improvement in the fibrosis stage[9].

The emergence of DAAs with their extended patient spectrum, improved efficacy, and safety profile increased our expectations regarding a decrease in HCC occurrence and recurrence. However, unpleasant data from new studies showed that DAAs might encourage tumor occurrence in patients with cirrhosis or recurrence in patients with previously treated HCC[9,17]. The same was reported in some studies regarding HCC.
Table 2 Clinical presentation in both groups

|                      | Group I | Group II | $P$ value |
|----------------------|---------|----------|-----------|
|                      | HCC with previous DAAs ($n = 151$) | HCC without previous DAAs ($n = 346$) |           |
| Hypertension         | 56 (37.1) | 135 (39.0) | 0.68 |
| DM                   | 56 (37.1) | 113 (32.7) | 0.33 |
| Smoking              | 73 (48.3) | 121 (35.0) | 0.005$^*$ |
| Surgical operations  | 32 (21.2) | 101 (29.2) | 0.06 |
| Blood transfusion    | 23 (15.2) | 87 (25.1) | 0.01$^a$ |
| Jaundice             | 60 (39.7) | 154 (44.5) | 0.32 |
| Ascites              | 90 (59.6) | 197 (56.9) | 0.58 |
| LL edema             | 48 (31.8) | 143 (41.3) | 0.07 |
| Hepatic encephalopathy | 14 (9.3) | 61 (17.6) | 0.01$^a$ |

$^aP < 0.05.$

HCC: Hepatocellular carcinoma; DM: Diabetes mellitus; LL: Lower limb.

Table 3 Comparison of laboratory data in both groups

|                      | Group I | Group II | $P$ value |
|----------------------|---------|----------|-----------|
|                      | HCC with previous DAAs ($n = 151$) | HCC without previous DAAs ($n = 346$) |           |
| HB (mean ± SD)       | 10.41 ± 1.88 | 10.78 ± 1.99 | 0.02$^a$ |
| TLC (mean ± SD)      | 6.55 ± 6.20 | 7.74 ± 8.60 | 0.004$^b$ |
| PLATELETS (mean ± SD)| 147.28 ± 79.76 | 135.95 ± 61.17 | 0.22 |
| TBIL (median)        | 3.07     | 2.5      | 0.93      |
| DBIL (median)        | 0.7      | 0.9      | 0.84      |
| ALB (mean ± SD)      | 3.32 ± 1.47 | 2.98 ± 0.85 | 0.004$^c$ |
| INR      | 1.31 ± 0.35 | 1.44 ± 0.47 | 0.4 |
| ALT (median)         | 77       | 54       | 0.001$^d$ |
| AST (median)         | 76       | 70       | 0.62      |
| CREAT (mean ± SD)    | 1.21 ± 0.45 | 1.43 ± 3.67 | 0.15 |
| UREA (mean ± SD)     | 40.81 ± 16.01 | 54.93 ± 46.17 | 0.04$^e$ |
| AFP (median)         | 184.0    | 60.0     | < 0.001$^f$ |

$^aP < 0.05.$

$^bP < 0.01.$

$^cP < 0.001.$

HCC: Hepatocellular carcinoma; CBC: Complete blood picture; TLC: Total leucocytic count; TBIL: Total bilirubin; DBIL: Direct bilirubin; ALB: Albumin, ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alfa feto protein.

This study stands at the current dilemma between DAAs’ benefits and drawbacks; studying the basic characteristics of HCC patients previously treated with DAAs and comparing them with people who have HCC patients never treated with DAAs provides the central part of this controversy.

In accordance with our results, a large study from Pakistan reported a raised neutrophil to lymphocyte ratio and younger patient age with more aggressive tumor recurrence after initial management upon treatment with DAAs[18].

In our study, significant differences were found in the CTP, MELD, and BCLC scores in HCC patients without DAAs and those who received DAAs; these findings are contrary to what proved by Abdelaziz et al[19], who found matching between patients with HCC and previous DAAs and HCC without DAAs regarding CTP score.
Table 4 Radiological characters of hepatocellular carcinoma in both groups

|                | Group I                  | Group II                 | P valuea |
|----------------|--------------------------|--------------------------|----------|
| Number         |                          |                          | < 0.001  |
| Single         | 71 (47.0)                | 259 (74.9)               |          |
| Multiple       | 80 (53.0)                | 87 (25.1)                |          |
| Size           |                          |                          | < 0.001  |
| Less than 2 cm | 1 (0.7)                  | 54 (15.6)                |          |
| 2.5 cm         | 91 (60.3)                | 177 (51.2)               |          |
| Greater than 5 cm | 59 (39.1)           | 115 (33.2)               |          |
| Site           |                          |                          | 0.001    |
| Bilobar        | 21 (13.9)                | 29 (8.4)                 |          |
| Lt lobe        | 24 (15.9)                | 23 (6.6)                 |          |
| RT lobe        | 106 (70.2)               | 294 (84.9)               |          |
| PVT            | 68 (45.0)                | 75 (21.7)                | < 0.001  |
| Splenomegaly   |                          |                          | < 0.001  |
| Average        | 38 (25.2)                | 98 (28.3)                |          |
| Mild           | 113 (74.8)               | 214 (61.8)               |          |
| Moderate       | 0 (0.0)                  | 34 (9.8)                 |          |

aP < 0.001.
HCC: Hepatocellular carcinoma; DAAs: Directly acting antiviral agents; PVT: Portal vein thrombosis.

behavior in HCV-treated HCC patients[20].

The pattern of HCC invasion either locally inside the liver manifested by multiplicity and larger size or vascularly manifested by PVT is significantly increased with the previous history of DAAs, suggesting a possible DAAs role in such aggressive behavior. In accordance with the current study, Reig et al[6] stated the increased aggressiveness of HCC, but in recurrent cases, he omitted de novo HCC in his study. Also, Renzulli et al[10] noticed a faster rate of development of HCC after DAA therapy with an aggressive course of microvascular invasion. Similarly, Faillaci et al[21] proved that DAAs are associated with increased aggressiveness and tumor recurrence growth. Another study done by Romano et al[21] demonstrated an aggressive behavior of tumors after DAA in the form of a higher number of nodules and extrahepatic metastases, suggesting that such patients' tumor growth is faster than usual Many theories have been proposed to explain this unexpected event; some researchers have related the development of HCC to baseline risk factors such as advanced fibrosis grade, HBV co-infection, or age[7]. Another theory proposes that DAAs cause immune surveillance mechanisms to become dysregulated due to the rapid viral clearance, and this behavior has been confirmed by several investigations [16,19]. With the downregulation of type II and III IFNs, their receptors, and IFN-stimulated genes, this dysregulation may result in the re-establishment of innate immunity. Due to the anti-angiogenic and anti-proliferative capabilities of IFN, which DAAs lack, a reduction in IFN activation may promote the proliferation of malignant cells. Furthermore, after HCV eradication, one of the immune system alterations observed is a decrease in the number of cytotoxic activity of natural killer cells in the liver, favoring a faster progression of HCC foci[7,22].

A significant difference was observed in AFP levels between the two groups, explained mainly by the invasive pattern and prominent vascular invasion in group I, and this is in agreement with Abdelaziz et al[20].

The strengths of our study include its design and the large number of included subjects. Limitations include the exclusive existence of genotype four patients because of its prevalence in Egypt and lack of tight evaluation of other risk factors for HCC, like non-alcoholic fatty liver disease and aflatoxin effect, and the lack of further longitudinal follow up of the studied cohort.
CONCLUSION

In conclusion, despite the introduction of newer DAAs, HCV-related HCC will continue to be a significant public health concern in the coming period. Post-treatment HCV-related HCC has been discovered to be an emerging issue due to unmet needs for early HCC identification and intervention. In this study, more aggressive tumor behavior was encountered in DAAs exposed patients. Such finding needs to be investigated further in prospective studies with larger cohorts and more longitudinal follow-up for comparing survival and necessitates proactive screening for HCC in HCV-treated patients via public or private pharmacovigilance programs. Furthermore, anti-HCV therapy in HCC patients should be postponed until a consistent risk-benefit ratio is established through further research.

ARTICLE HIGHLIGHTS

Research background
The evidence on the link between direct-acting antivirals (DAAs) and the development of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) patients is insufficient and conflicting.

Research motivation
Due to unmet needs for early HCC detection and care, post-treatment HCV-related HCC is an increasing concern.

Research objectives
To compare fundamental clinical, radiographic, and laboratory features and tumor behavior in individuals with and without a history of DAAs exposure after HCC diagnosis.

Research methods
A multicenter case-control study including 497 patients with chronic HCV-related HCC, allocated into one of two groups according to their history of antiviral treatment for their HCV.

Research results
Group I consisted of 151 HCC patients who had previously been treated with DAAs, while group II included 346 patients who had never been treated with DAAs. Regarding basic assessment scores (Child, MELD, and BCLC), there was a substantial difference between the two groups, with group I showing a tendency for more advanced liver disease and HCC stage at diagnosis. However, serum albumin levels were considerably lower in group II, and serum-fetoprotein levels were significantly greater ($P = 0.001$). In addition, HCC multicentricity was substantially higher in group I than in group II, and the rate of portal vein thrombosis was significantly higher in group I ($P = 0.001$).

Research conclusions
HCC patients who are naïve to DAAs have more advanced clinical scores and laboratory features than those who have never been treated with DAAs; yet, HCC behavior is more aggressive in DAA-treated patients.

Research perspectives
The findings of this study warrant additional investigation in prospective trials with larger cohorts and longer follow-up for comparing survival and proactive screening for HCC in HCV-treated patients through public or private pharmacovigilance programs.

ACKNOWLEDGEMENTS
The authors acknowledge the physicians of Minia University who helped in this research.
Abdelaziz AO, Nabil MM, Abdelmaksoud AH, Shousha HI, Hashem MB, Hassan EM, Salah A, 

REFERENCES

1 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. *World J Gastroenterol* 2014; 20: 10223-10237 [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223]

2 Holah NS, El-Azab DS, Aiad HAE, Sweed DMM. The Diagnostic Role of SPINK1 in Differentiating Hepatocellular Carcinoma From Nonmalignant Lesions. *Appl Immunohistochem Mol Morphol* 2017; 25: 703-711 [PMID: 27028422 DOI: 10.1097/PAI.0000000000000363]

3 Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology* 2015; 61: 77-87 [PMID: 25066598 DOI: 10.1002/hep.27259]

4 Kandeel A, Genody M, El-Refu S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. *Liver Int* 2017; 37: 45-53 [PMID: 27275263 DOI: 10.1111/liv.13186]

5 Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2007; 5: 938-945, 945.e1 [PMID: 17509946 DOI: 10.1016/j.cgh.2007.02.039]

6 Reig M, Mariño Z, Perelló C, Íñarraíraegui M, Ribeiro A, Lens S, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. *J Hepatol* 2016; 65: 719-726 [PMID: 27845992 DOI: 10.1016/j.jhep.2016.04.008]

7 El Kassas M, Elbhz T, Salaheldin M, Abdelsalam A, Kaseb A, Esmat G. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues - A mini-review. *J Adv Res* 2019; 17: 43-48 [PMID: 31193326 DOI: 10.1016/j.jare.2019.03.001]

8 Tanimoto Y, Tashiro H, Akata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T, Chayama K, Ohdan H. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. *Ann Surg Oncol* 2012; 19: 418-425 [PMID: 21710324 DOI: 10.1245/s10434-011-1866-1]

9 Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Veracchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *J Hepatol* 2016; 65: 727-733 [PMID: 27349488 DOI: 10.1016/j.jhep.2016.06.015]

10 Renzulli M, Buonfiglioli F, Conti F, Brocchi S, Serio I, Foschi FG, Caraceni P, Mazzella G, Veracchi G, Golifiri R, Andreone P, Brillanti S. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. *Eur Radiol* 2018; 28: 506-513 [PMID: 28894091 DOI: 10.1007/s00330-017-5033-3]

11 Bruix J, Sherman M, Llovet JM, Lencioni R, Burroughs AK, Diener MS; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* 2001; 35: 421-430 [PMID: 11592607 DOI: 10.1016/s0168-8278(01)00130-1]

12 Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

13 Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Saladrigues J, Cervera J, Ros J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology* 1999; 29: 62-67 [PMID: 9862851 DOI: 10.1002/hep.24199]

14 Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Spooner RR, Curto TM, Vierling JM, Sanyal AJ; HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. *Gastroenterology* 2009; 136: 138-148 [PMID: 18848939 DOI: 10.1053/j.gastro.2008.09.014]

15 Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. *Gastroenterology* 2010; 139: 1593-1601 [PMID: 20637202 DOI: 10.1053/j.gastro.2010.07.009]

16 Robert S B Jr. The Possible Association Between DAA Treatment for HCV Infection and HCC Recurrence. *Gastroenterol Hepatol (N Y)* 2016; 12: 776-779 [PMID: 28035203]

17 Tayyab GUN, Rasool S, Nasir B, Rubi G, Abou-Samra AB, Butt AA. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens. * BMC Gastroenterol* 2020; 20: 93 [PMID: 32252635 DOI: 10.1186/s12876-020-01249-4]

18 Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoeda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Assahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchanté N, Cavalletto L, Chenello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Caminé C, Bruix J, Cabibbo G, Reig M. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. *Gut* 2021 [DOI: 10.1136/gutjnl-2020-323663]

19 Abdelaziz AO, Nabil MM, Abdelmaksoud AH, Shousha HI, Hashem MB, Hassan EM, Salah A,
Omran DA, Elbaz TM. Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients. *Eur J Gastroenterol Hepatol* 2019; **31**: 75-79 [PMID: 30199473 DOI: 10.1097/MEG.0000000000001264]

Khalid J, Umar M, Ur-Rehman T, Ali M, Khan GM. Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy. *Infect Agent Cancer* 2020; **15**: 35 [PMID: 32508980 DOI: 10.1186/s13027-020-00300-z]

Faillaci F, Marzi L, Critelli R, Milosa F, Schepis F, Turola E, Andreani S, Vandelli G, Bernabucci V, Lei B, D’Ambrosio F, Brisot L, Cavalletto L, Chemello L, Sighinolfi P, Manni P, Maiorana A, Caporalì C, Bianchini M, Marsico M, Turco L, de Maria N, Del Buono M, Todesca P, di Lena L, Romagnoli D, Magistri P, di Benedetto F, Bruno S, Taliani G, Giannelli G, Martinez-Chantar ML, Villa E. Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals. *Hepatology* 2018; **68**: 1010-1024 [PMID: 29604220 DOI: 10.1002/hep.29911]

Innes H, Barclay ST, Hayes PC, Fraser A, Dillon JF, Stanley A, Bathgate A, McDonald SA, Goldberg D, Valerio H, Fox R, Kennedy N, Bramley P, Hutchinson SJ. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. *J Hepatol* 2018; **68**: 646-654 [PMID: 29155019 DOI: 10.1016/j.jhep.2017.10.033]
